George Budwell
George Budwell, Ph.D., is a contributing Biotechnology and Technology Analyst at The Motley Fool, covering disruptive innovators in healthcare, defense, and artificial intelligence, and writing on portfolio theory, dividend stocks, and value investing. Prior to The Motley Fool, George was a freelance medical and science writer for various organizations, as well as an independent consultant for multiple life sciences-oriented hedge funds. In a former life, he was an evolutionary biologist, having completed two postdoctoral fellowships at Kyoto University and Illinois State University, respectively. He holds a Ph.D. in Evolutionary Biology from Tulane University and a B.S. (pre-med) from Loyola University. Fun fact: George is an avid golfer, nature enthusiast, and proud father of four.
Recent Articles by George Budwell

3 Reasons Nvidia Stock Is a Forever Buy and Hold

3 Incredible Growth Stocks I Can't Stop Buying

Is Nike a Top Buy in 2025?

This Unpopular Dividend Stock Is a Buy

Is Walmart Stock a Buy in 2025?

Is Rigetti Computing Stock a Buy in 2025?

Is D-Wave Quantum Inc. Stock a Buy in 2025?

2 High-Yield Dividend Stocks to Buy Early in 2025

Better Income Stock: Pfizer or Altria Group?

My Top 2 AI Stocks for 2025
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.